CRISPR Therapeutics AG (CRSP) earnings
- Jun 2026
- Dec 2025
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 10.2 | +1041.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -1151.8 | +24557.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -91.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$50.04 +1.60% · +$0.79
Performance −27.6% 1Y
1Y: $69.15 on 17 Oct 2025 → $50.04. High $73.97 (20 Oct 2025), low $44.34 (30 Mar 2026).
- Previous close
- $49.25
- 52-week range
- $44.34 – $73.97
- One year
- −32.35%
Overview
- Symbol
- CRSP
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Financials
What the filings say
Net profit, year on year: +56% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 36 | 1 | 1 | 1 | 1 | 1 | 10 |
| Operating profit | -110 | -65 | -148 | -229 | -132 | -155 | -130 | -117 |
| Operating margin | −18294.0% | −181.0% | −17158.8% | −25709.0% | −14854.8% | −17912.5% | −8933.3% | −1151.8% |
| Other income | 25 | 28 | 14 | 22 | 26 | 25 | 8 | 27 |
| Profit before tax | -85 | -37 | -135 | -207 | -106 | -130 | -122 | -90 |
| Tax rate | −1.0% | −1.9% | −0.8% | −0.6% | −0.6% | −0.5% | −0.7% | −1.1% |
| Net profit | -86 | -37 | -136 | -209 | -106 | -131 | -123 | -91 |
| EPS ($ per share) | -1.01 | — | -1.58 | -2.40 | -1.17 | — | -1.28 | -0.94 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 |
| Reserves | -292 | -225 | -574 | -196 | -846 | -1,000 | -1,366 | -1,948 |
| Total liabilities | 97 | 127 | 164 | 352 | 368 | 347 | 310 | 343 |
| Fixed assets | 19 | 31 | 42 | 138 | 164 | 152 | 134 | 116 |
| Investments | — | 0 | 522 | 1,456 | 1,603 | 1,304 | 1,606 | 1,628 |
| Total assets | 489 | 1,067 | 1,828 | 2,752 | 2,243 | 2,230 | 2,242 | 2,265 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -96 | 57 | -238 | 539 | -496 | -260 | -143 | -345 |
| Cash from investing | -3 | 1 | -541 | -1,035 | -259 | 375 | -280 | -32 |
| Cash from financing | 316 | 431 | 1,016 | 251 | 39 | 63 | 332 | 426 |
| Net cash flow | 217 | 489 | 237 | -246 | -716 | 177 | -91 | 49 |
| Capital expenditure | -3 | -7 | -18 | -82 | -37 | -9 | -2 | -1 |
| Free cash flow | -99 | 50 | -257 | 457 | -533 | -270 | -145 | -346 |
CRSP revenue by segment
Collaboration Revenue grew from 0% to 98% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue | 0% | 98% | 0% | 0% | 0% | 0% | 69% | 98% | — |
| Grant | 100% | 2% | 100% | 100% | 100% | 100% | 31% | 2% | -79.7% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
54 filings between Dec 18, 2025 and Oct 14, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$15.56M
29 sales by 6 insiders
45% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 22
- Option exercise — converted options into shares
Also filed: 3 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Kulkarni Samarth | — | $7.22M | Oct 14, 2026 |
| Prasad Raju | — | $5.10M | Mar 23, 2026 |
| KASINGER JAMES R. | — | $1.37M | Oct 14, 2026 |
| Behbahani Ali | — | $780.9K | Sep 17, 2026 |
| George Simeon | — | $720.4K | Oct 14, 2026 |
| Patel Naimish | — | $362.6K | May 29, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 14, 2026 | George Simeon Director | Option exercise 10b5-1 plan | 30,000 | $420.0K |
| Oct 14, 2026 | George Simeon Director | Sale 10b5-1 plan | 14,514 | $720.4K |
| Oct 14, 2026 | Kulkarni Samarth Chief Executive Officer | Sale | 4,098 | $201.9K |
| Oct 14, 2026 | KASINGER JAMES R. General Counsel and Secretary | Sale | 1,040 | $51.2K |
| Oct 13, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | 2,113 | — |
| Oct 13, 2026 | Kulkarni Samarth Chief Executive Officer | Option exercise | 8,333 | — |
| Oct 6, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise 10b5-1 plan | 1,990 | $27.1K |
| Oct 6, 2026 | KASINGER JAMES R. General Counsel and Secretary | Sale 10b5-1 plan | 1,990 | $119.5K |
| Sep 22, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise 10b5-1 plan | 10,400 | $141.6K |
| Sep 22, 2026 | KASINGER JAMES R. General Counsel and Secretary | Sale 10b5-1 plan | 10,400 | $626.5K |
| Sep 17, 2026 | Behbahani Ali Director | Option exercise | 30,000 | $420.0K |
| Sep 17, 2026 | Behbahani Ali Director | Sale | 13,679 | $780.9K |
| Aug 7, 2026 | Prasad Raju Chief Financial Officer | Gift | 750 | $0 |
| May 29, 2026 | Patel Naimish Chief Medical Officer | Sale | 3,786 | $210.6K |
| May 28, 2026 | Patel Naimish Chief Medical Officer | Option exercise | 10,000 | — |
| Mar 23, 2026 | Kulkarni Samarth Chief Executive Officer | Sale | 10,020 | $468.7K |
| Mar 23, 2026 | KASINGER JAMES R. General Counsel and Secretary | Sale | 3,182 | $148.9K |
| Mar 23, 2026 | Prasad Raju Chief Financial Officer | Sale | 3,708 | $173.5K |
| Mar 20, 2026 | Kulkarni Samarth Chief Executive Officer | Option exercise | 19,687 | — |
| Mar 20, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | 6,250 | — |
| Mar 20, 2026 | Prasad Raju Chief Financial Officer | Option exercise | 6,250 | — |
| Mar 16, 2026 | KASINGER JAMES R. General Counsel and Secretary | Sale | 3,450 | $166.5K |
| Mar 16, 2026 | Patel Naimish Chief Medical Officer | Sale | 3,150 | $152.0K |
| Mar 16, 2026 | Prasad Raju Chief Financial Officer | Gift | 750 | $0 |
| Mar 16, 2026 | Prasad Raju Chief Financial Officer | Sale | 5,848 | $282.2K |
| Mar 16, 2026 | Prasad Raju Chief Financial Officer | Sale | 4,021 | $194.1K |
| Mar 16, 2026 | Kulkarni Samarth Chief Executive Officer | Sale | 10,349 | $499.4K |
| Mar 14, 2026 | Prasad Raju Chief Financial Officer | Option exercise | 6,875 | — |
| Mar 14, 2026 | Prasad Raju Chief Financial Officer | Option exercise | 10,000 | — |
| Mar 14, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | 6,875 | — |
| Mar 14, 2026 | Patel Naimish Chief Medical Officer | Option exercise | 8,125 | — |
| Mar 14, 2026 | Kulkarni Samarth Chief Executive Officer | Option exercise | 20,625 | — |
| Mar 11, 2026 | KASINGER JAMES R. General Counsel and Secretary | Sale | 2,800 | $147.8K |
| Mar 11, 2026 | Kulkarni Samarth Chief Executive Officer | Sale | 9,798 | $517.3K |
| Mar 10, 2026 | Kulkarni Samarth Chief Executive Officer | Option exercise | 19,250 | — |
| Mar 10, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | 5,500 | — |
| Feb 19, 2026 | Kulkarni Samarth Chief Executive Officer | Sale | 6,967 | $366.3K |
| Feb 19, 2026 | KASINGER JAMES R. General Counsel and Secretary | Sale | 2,112 | $111.0K |
| Feb 18, 2026 | Kulkarni Samarth Chief Executive Officer | Option exercise | 13,250 | — |
| Feb 18, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | 3,825 | — |
| Jan 22, 2026 | Prasad Raju Chief Financial Officer | Sale 10b5-1 plan | 34,972 | $2.10M |
| Jan 22, 2026 | Prasad Raju Chief Financial Officer | Option exercise 10b5-1 plan | 34,972 | $1.58M |
| Jan 22, 2026 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 plan | 60,000 | $3.61M |
| Jan 20, 2026 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 plan | 21,433 | $1.11M |
| Jan 20, 2026 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 plan | 8,567 | $446.3K |
| Jan 6, 2026 | Prasad Raju Chief Financial Officer | Sale 10b5-1 plan | 5,004 | $300.2K |
| Jan 6, 2026 | Prasad Raju Chief Financial Officer | Sale 10b5-1 plan | 5,763 | $347.0K |
| Jan 6, 2026 | Prasad Raju Chief Financial Officer | Sale 10b5-1 plan | 18,933 | $1.14M |
| Jan 6, 2026 | Prasad Raju Chief Financial Officer | Option exercise 10b5-1 plan | 6,339 | $280.9K |
| Jan 6, 2026 | Prasad Raju Chief Financial Officer | Option exercise 10b5-1 plan | 23,361 | $1.05M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CRISPR Therapeutics AG
Free account. Everything above stays public.
Write why you follow CRISPR Therapeutics AG and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading